Willow Biosciences Inc. Share Price Canadian Securities Exchange
Equities
WLLW
CA97111B4047
Pharmaceuticals
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CAD | -.--% | -.--% | -.--% |
04-01 | Willow Biosciences Narrows 2023 Loss YOY | MT |
03-29 | Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2022 | 821K 599K 47.82M | Sales 2023 | 1.17M 856K 68.26M | Capitalization | 12.42M 9.07M 724M |
---|---|---|---|---|---|
Net income 2022 | -14M -10.22M -815M | Net income 2023 | -13M -9.49M -757M | EV / Sales 2022 | -0.95 x |
Net cash position 2022 | 15.01M 10.96M 874M | Net cash position 2023 | 1.63M 1.19M 94.82M | EV / Sales 2023 | 9.21 x |
P/E ratio 2022 |
-0.96
x | P/E ratio 2023 |
-0.95
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.66% |
Managers | Title | Age | Since |
---|---|---|---|
Chris Savile
CEO | Chief Executive Officer | - | 11/04/19 |
Travis Doupe
DFI | Director of Finance/CFO | - | 11/04/19 |
Trish Choudhary
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jim Lalonde
CHM | Chairman | 63 | 20/02/23 |
Donald Archibald
BRD | Director/Board Member | 63 | 11/04/19 |
Director/Board Member | 51 | 11/04/19 |
1st Jan change | Capi. | |
---|---|---|
-3.79% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B |
- Stock Market
- Equities
- WLLW Stock
- WLLW Stock